Teleseminar on Comparative Patent Enablement
Date: January 18, 2006
Time: 12:30 PM Eastern
Duration: 1 Hour
Contact Info@aplf.org for the dial-in number
"Patent Enablement and Written Description: A View from the United States, Europe and Canada"
Outline of Talk:
It is a basic tenet of patent law that a patent provide a comprehensive description of the invention and that the invention be "enabled". However, there exists a thicket of confusing and sometimes contradictory case law on this requirement. While this topic is of particular relevance to pharmaceutical and biotechnology patents, it is certainly not limited to these fields. It is critical to thoroughly understand what these requirements mean in practice and to keep abreast of recent cases. Europe, United States and Canada all apply subtly different approaches to the issue. We will discuss recent decisions on this topic and summarize the current state of the laws in these jurisdictions. We will also consider whether the laws in these jurisdictions are converging or diverging in this area, and practical steps that practitioners can take to ensure that these requirement are met.
The presenters welcome suggestions/questions from potential listeners on any specific topic that they wish addressed at the presentation. Please email suggestions/questions to azahl@ridoutmaybee.com
Presenters:
Adrian Zahl [azahl@ridoutmaybee.com] from Ridout & Maybee LLP
Dr. Dirk Bühler [Buehler@maiwald.de] from Maiwald Patentanwalts GmbH
Michael R. Dzwonczyk [mdzwonczyk@sughrue.com] from Sughrue Mion, PLLC
Martin Huenges [Huenges@maiwald.de] from Maiwald Patentanwalts GmbH
Time: 12:30 PM Eastern
Duration: 1 Hour
Contact Info@aplf.org for the dial-in number
"Patent Enablement and Written Description: A View from the United States, Europe and Canada"
Outline of Talk:
It is a basic tenet of patent law that a patent provide a comprehensive description of the invention and that the invention be "enabled". However, there exists a thicket of confusing and sometimes contradictory case law on this requirement. While this topic is of particular relevance to pharmaceutical and biotechnology patents, it is certainly not limited to these fields. It is critical to thoroughly understand what these requirements mean in practice and to keep abreast of recent cases. Europe, United States and Canada all apply subtly different approaches to the issue. We will discuss recent decisions on this topic and summarize the current state of the laws in these jurisdictions. We will also consider whether the laws in these jurisdictions are converging or diverging in this area, and practical steps that practitioners can take to ensure that these requirement are met.
The presenters welcome suggestions/questions from potential listeners on any specific topic that they wish addressed at the presentation. Please email suggestions/questions to azahl@ridoutmaybee.com
Presenters:
Adrian Zahl [azahl@ridoutmaybee.com] from Ridout & Maybee LLP
Dr. Dirk Bühler [Buehler@maiwald.de] from Maiwald Patentanwalts GmbH
Michael R. Dzwonczyk [mdzwonczyk@sughrue.com] from Sughrue Mion, PLLC
Martin Huenges [Huenges@maiwald.de] from Maiwald Patentanwalts GmbH
0 Comments:
Post a Comment
<< Home
© 2004-2007 William F. Heinze